A randomized, double-blind comparison of atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention deficit and disruptive behaviour disorders; Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 02 Mar 2010 Actual end date (Jan 2009) and actual number of patients (181) added as reported by ClinicalTrials.gov.
- 02 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.